Baziel van Engelen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2331136/publications.pdf

Version: 2024-02-01

508 papers	21,037 citations	9264 74 h-index	19190 118 g-index
527 all docs	527 docs citations	527 times ranked	17009 citing authors

#	Article	IF	Citations
1	Development and validation of the patient-reported â€œFacial Function Scaleâ€•for facioscapulohumeral muscular dystrophy. Disability and Rehabilitation, 2023, 45, 1530-1535.	1.8	2
2	Chromosome 10q-linked FSHD identifies DUX4 as principal disease gene. Journal of Medical Genetics, 2022, 59, 180-188.	3.2	18
3	Facioscapulohumeral muscular dystrophyâ€”Reproductive counseling, pregnancy, and delivery in a complex multigenetic disease. Clinical Genetics, 2022, 101, 149-160.	2.0	5
4	High-resolution breakpoint junction mapping of proximally extended D4Z4 deletions in FSHD1 reveals evidence for a founder effect. Human Molecular Genetics, 2022, 31, 748-760.	2.9	8
5	Experiences of patients with facioscapulohumeral dystrophy with facial weakness: a qualitative study. Disability and Rehabilitation, 2022, 44, 6775-6782.	1.8	3
6	N-of-1 Trials in Neurology. Neurology, 2022, 98, .	1.1	7
7	Facioscapulohumeral dystrophy transcriptome signatures correlate with different stages of disease and are marked by different MRI biomarkers. Scientific Reports, 2022, 12, 1426.	3.3	14
8	Long-term follow-up of respiratory function in facioscapulohumeral muscular dystrophy. Journal of Neurology, 2022, 269, 3682-3689.	3.6	2
9	Visuomotor processing is altered after peripheral nerve damage in neuralgic amyotrophy. Brain Communications, 2022, 4, fcac034.	3.3	2
10	Neurological features of Noonan syndrome and related <scp>RASopathies</scp> : Pain and nerve enlargement characterized by nerve ultrasound. American Journal of Medical Genetics, Part A, 2022, , .	1.2	3
11	Blood Transcriptome Profiling Links Immunity to Disease Severity in Myotonic Dystrophy Type 1 (DM1). International Journal of Molecular Sciences, 2022, 23, 3081.	4.1	3
12	Quantitative Muscle Analysis in Facioscapulohumeral Muscular Dystrophy Using <scp>Wholeâ€Body Fatâ€Referenced MRI</scp> : Protocol Development, Multicenter Feasibility, and Repeatability. Muscle and Nerve, 2022, , .	2.2	1
13	Reachable workspace analysis is a potential measurement for impairment of the upper extremity in neuralgic amyotrophy. Muscle and Nerve, 2022, 66, 282-288.	2.2	2
14	Respiratory muscle function in patients with nemaline myopathy. Neuromuscular Disorders, 2022, 32, 654-663.	0.6	7
15	Electrocardiographic predictors of infrahissian conduction disturbances in myotonic dystrophy type 1. Europace, 2021, 23, 298-304.	1.7	18
16	Systemic cell therapy for muscular dystrophies. Stem Cell Reviews and Reports, 2021, 17, 878-899.	3.8	11
17	Characterizing the face in facioscapulohumeral muscular dystrophy. Journal of Neurology, 2021, 268, 1342-1350.	3.6	13
18	Reduced specific force in patients with mild and severe facioscapulohumeral muscular dystrophy. Muscle and Nerve, 2021, 63, 60-67.	2.2	9

#	Article	IF	Citations
19	Semiâ€automated Rasch analysis using inâ€plusâ€outâ€ofâ€questionnaire log likelihood. British Journal of Mathematical and Statistical Psychology, 2021, 74, 313-339.	1.4	3
20	New Insights in Adherence and Survival in Myotonic Dystrophy Patients Using Home Mechanical Ventilation. Respiration, 2021, 100, 154-163.	2.6	6
21	Noninvasive Home Mechanical Ventilation in Adult Myotonic Dystrophy Type 1: A Systematic Review. Respiration, 2021, 100, 816-825.	2.6	5
22	Human brain pathology in myotonic dystrophy type 1: A systematic review. Neuropathology, 2021, 41, 3-20.	1.2	21
23	NEM6, KBTBD13-Related Congenital Myopathy: Myopathological Analysis in 18 Dutch Patients Reveals Ring Rods Fibers, Cores, Nuclear Clumps, and Granulo-Filamentous Protein Material. Journal of Neuropathology and Experimental Neurology, 2021, 80, 366-376.	1.7	4
24	Associations Between Variant Repeat Interruptions and Clinical Outcomes in Myotonic Dystrophy Type 1. Neurology: Genetics, 2021, 7, e572.	1.9	10
25	Respiratory muscle imaging by ultrasound and MRI in neuromuscular disorders. European Respiratory Journal, 2021, 58, 2100137.	6.7	5
26	Second intravenous immunoglobulin dose in patients with Guillain-BarrÃ© syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. Lancet Neurology, The, 2021, 20, 275-283.	10.2	34
27	The socioeconomic burden of facioscapulohumeral muscular dystrophy. Journal of Neurology, 2021, 268, 4778-4788.	3.6	5
28	Antiâ€“Cytosolic 5â€²â€Nucleotidase 1A Autoantibodies Are Absent in Juvenile Dermatomyositis. Arthritis and Rheumatology, 2021, 73, 1329-1333.	5.6	2
29	Phase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: Safety, tolerability, pharmacokinetics, and target engagement. British Journal of Clinical Pharmacology, 2021, 87, 4658-4669.	2.4	20
30	The facioscapulohumeral muscular dystrophy Raschâ€built overall disability scale (FSHDâ€RODS). European Journal of Neurology, 2021, 28, 2339-2348.	3.3	8
31	N-of-1 trial of salbutamol in hyperkalaemic periodic paralysis. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, jnnp-2021-326347.	1.9	1
32	Behavioural Impairment and Frontotemporal Dementia in Oculopharyngeal Muscular Dystrophy. Journal of Neuromuscular Diseases, 2021, , 1-7.	2.6	1
33	Clinical Outcome Evaluations and CBT Response Prediction in Myotonic Dystrophy. Journal of Neuromuscular Diseases, 2021, 8, 1031-1046.	2.6	4
34	Exploring the influence of smoking and alcohol consumption on clinical severity in patients with facioscapulohumeral muscular dystrophy. Neuromuscular Disorders, 2021, 31, 824-828.	0.6	1
35	Longitudinal Assessment of Strength, Functional Capacity, Oropharyngeal Function, and Quality of Life in Oculopharyngeal Muscular Dystrophy. Neurology, 2021, 97, e1475-e1483.	1.1	11
36	Mixed methods evaluation of a self-management group programme for patients with neuromuscular disease and chronic fatigue. BMJ Open, 2021, 11, e048890.	1.9	3

#	Article	IF	Citations
37	The neuromuscular and multisystem features of RYR1-related malignant hyperthermia and rhabdomyolysis. Medicine (United States), 2021, 100, e26999.	1.0	8
38	Natural history, outcome measures and trial readiness in LAMA2-related muscular dystrophy and SELENON-related myopathy in children and adults: protocol of the LAST STRONG study. BMC Neurology, 2021, 21, 313.	1.8	12
39	Clinical, genetic, and histological features of centronuclear myopathy in the Netherlands. Clinical Genetics, 2021, 100, 692-702.	2.0	7
40	Profiling Serum Antibodies Against Muscle Antigens in Facioscapulohumeral Muscular Dystrophy Finds No Disease-Specific Autoantibodies. Journal of Neuromuscular Diseases, 2021, 8, 801-814.	2.6	6
41	MYOTONIC DYSTROPHY. Neuromuscular Disorders, 2021, 31, S121.	0.6	0
42	FSHD. Neuromuscular Disorders, 2021, 31, S99-S100.	0.6	0
43	FSHD. Neuromuscular Disorders, 2021, 31, S100.	0.6	0
44	CONGENITAL MUSCULAR DYSTROPHIES. Neuromuscular Disorders, 2021, 31, S70.	0.6	0
45	CONGENITAL MYOPATHIES. Neuromuscular Disorders, 2021, 31, S65.	0.6	0
46	Rasch analysis to evaluate the motor function measure for patients with facioscapulohumeral muscular dystrophy. International Journal of Rehabilitation Research, 2021, 44, 38-44.	1.3	13
47	Natural History of Facioscapulohumeral Dystrophy in Children. Neurology, 2021, 97, e2103-e2113.	1.1	7
48	Care for capabilities: Implementing the capability approach in rehabilitation of patients with neuromuscular diseases. Study protocol of the controlled before-after ReCap-NMD study. PLoS ONE, 2021, 16, e0261475.	2.5	1
49	Short fatigue questionnaire: Screening for severe fatigue.. Journal of Psychosomatic Research, 2020, 137, 110229.	2.6	17
50	Swallowing, Chewing and Speaking: Frequently Impaired in Oculopharyngeal Muscular Dystrophy. Journal of Neuromuscular Diseases, 2020, 7, 483-494.	2.6	8
51	CONGENITAL MYOPATHIES 1 â€“ NEMALINE. Neuromuscular Disorders, 2020, 30, S53.	0.6	0
52	CONGENITAL MYOPATHIES 1 â€“ NEMALINE. Neuromuscular Disorders, 2020, 30, S55.	0.6	0
53	FSHD / OPMD / MYOTONIC DYSTROPHY. Neuromuscular Disorders, 2020, 30, S112-S113.	0.6	0
54	FSHD / OPMD / MYOTONIC DYSTROPHY. Neuromuscular Disorders, 2020, 30, S113.	0.6	0

#	Article	IF	Citations
55	FSHD / OPMD / MYOTONIC DYSTROPHY. Neuromuscular Disorders, 2020, 30, S113.	0.6	0
56	Deep phenotyping of facioscapulohumeral muscular dystrophy type 2 by magnetic resonance imaging. European Journal of Neurology, 2020, 27, 2604-2615.	3.3	16
57	Clinical, morphological and genetic characterization of Brody disease: an international study of 40 patients. Brain, 2020, 143, 452-466.	7.6	22
58	Age-Associated Salivary MicroRNA Biomarkers for Oculopharyngeal Muscular Dystrophy. International Journal of Molecular Sciences, 2020, 21, 6059.	4.1	9
59	Correlation Between Quantitative MRI and Muscle Histopathology in Muscle Biopsies from Healthy Controls and Patients with IBM, FSHD and OPMD. Journal of Neuromuscular Diseases, 2020, 7, 495-504.	2.6	25
60	Swallowing, Chewing and Speaking: Frequently Impaired in Oculopharyngeal Muscular Dystrophy. Journal of Neuromuscular Diseases, 2020, 7, 1-12.	2.6	12
61	Quantitative Muscle MRI Depicts Increased Muscle Mass after a Behavioral Change in Myotonic Dystrophy Type 1. Radiology, 2020, 297, 132-142.	7.3	11
62	Inclusion body myositis in patients with spinocerebellar ataxia types 3 and 6. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 876-878.	1.9	2
63	Altered sensorimotor representations after recovery from peripheral nerve damage in neuralgic amyotrophy. Cortex, 2020, 127, 180-190.	2.4	10
64	Muscle ultrasound is a responsive biomarker in facioscapulohumeral dystrophy. Neurology, 2020, 94, e1488-e1494.	1.1	23
65	N-of-1 Trials: Evidence-Based Clinical Care or Medical Research that Requires IRB Approval? A Practical Flowchart Based on an Ethical Framework. Healthcare (Switzerland), 2020, 8, 49.	2.0	18
66	Characterization of EEG-based functional brain networks in myotonic dystrophy type 1. Clinical Neurophysiology, 2020, 131, 1886-1895.	1.5	1
67	Consequences of epigenetic derepression in facioscapulohumeral muscular dystrophy. Clinical Genetics, 2020, 97, 799-814.	2.0	40
68	Preserved single muscle fiber specific force in facioscapulohumeral muscular dystrophy. Neurology, 2020, 94, e1157-e1170.	1.1	8
69	Continued misuse of orphan drug legislation: a life-threatening risk for mexiletine. European Heart Journal, 2020, 41, 614-617.	2.2	15
70	Guidelines on clinical presentation and management of nondystrophic myotonias. Muscle and Nerve, 2020, 62, 430-444.	2.2	53
71	248th ENMC International Workshop: Myotonic dystrophies: Molecular approaches for clinical purposes, framing a European molecular research network, Hoofddorp, the Netherlands, 11â€“13 October 2019. Neuromuscular Disorders, 2020, 30, 521-531.	0.6	1
72	KBTBD13 is an actin-binding protein that modulates muscle kinetics. Journal of Clinical Investigation, 2020, 130, 754-767.	8.2	25

#	Article	IF	Citations
73	NA-CONTROL: a study protocol for a randomised controlled trial to compare specific outpatient rehabilitation that targets cerebral mechanisms through relearning motor control and uses self-management strategies to improve functional capability of the upper extremity, to usual care in patients with neuralgic amyotrophy. Trials, 2019, 20, 482.	1.6	9
74	SMCHD1 mutation spectrum for facioscapulohumeral muscular dystrophy type 2 (FSHD2) and Bosma arhinia microphthalmia syndrome (BAMS) reveals disease-specific localisation of variants in the ATPase domain. Journal of Medical Genetics, 2019, 56, 693-700.	3.2	27
75	Ophthalmological findings in facioscapulohumeral dystrophy. Brain Communications, 2019, 1, fcz023.	3.3	14
76	O.25Phase 1 clinical trial of losmapimod in FSHD: safety, tolerability and target engagement. Neuromuscular Disorders, 2019, 29, S123.	0.6	1
77	P.40Ophthalmological findings in facioscapulohumeral dystrophy. Neuromuscular Disorders, 2019, 29, S52-S53.	0.6	0
78	P.46Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, multi-center prospective study. Neuromuscular Disorders, 2019, 29, S54.	0.6	0
79	P.63Chronic progressive external ophthalmoplegia (CPEO) and CPEO-plus cohort of 54 patients from the Netherlands. Neuromuscular Disorders, 2019, 29, S59.	0.6	0
80	P.162Novel Kbtbd13R408C-knockin mouse model phenocopies NEM6 myopathy. Neuromuscular Disorders, 2019, 29, S95.	0.6	0
81	O.13Nemaline myopathy patients with mutations in KBTBD13 display a cardiac phenotype. Neuromuscular Disorders, 2019, 29, S118.	0.6	0
82	P.247Capturing disease progression in oculopharyngeal muscular dystrophy (OPMD). Neuromuscular Disorders, 2019, 29, S139.	0.6	0
83	P.306Multicentric MRI study in a cohort of FSHD2 patients: pattern definition and differences between FSHD1 and FSHD2. Neuromuscular Disorders, 2019, 29, S156.	0.6	0
84	High incidence of falls in patients with myotonic dystrophy type 1 and 2: A prospective study. Neuromuscular Disorders, 2019, 29, 758-765.	0.6	10
85	Scapular dyskinesis in myotonic dystrophy type 1: clinical characteristics and genetic investigations. Journal of Neurology, 2019, 266, 2987-2996.	3.6	1
86	Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study. BMC Neurology, 2019, 19, 224.	1.8	28
87	Effects of weakness of orofacial muscles on swallowing and communication in FSHD. Neurology, 2019, 92, e957-e963.	1.1	25
88	Lower extremity muscle pathology in myotonic dystrophy type 1 assessed by quantitative MRI. Neurology, 2019, 92, e2803-e2814.	1.1	34
89	MSH3 modifies somatic instability and disease severity in Huntingtonâ€™s and myotonic dystrophy type 1. Brain, 2019, 142, 1876-1886.	7.6	114
90	Panel-Based Exome Sequencing for Neuromuscular Disorders as a Diagnostic Service. Journal of Neuromuscular Diseases, 2019, 6, 241-258.	2.6	32

#	Article	IF	Citations
91	Muscle fiber dysfunction contributes to weakness in inclusion body myositis. Neuromuscular Disorders, 2019, 29, 468-476.	0.6	3
92	Autoantibody testing in idiopathic inflammatory myopathies. Practical Neurology, 2019, 19, 284-294.	1.1	16
93	Affective symptoms and apathy in myotonic dystrophy type 1 a systematic review and meta-analysis. Journal of Affective Disorders, 2019, 250, 260-269.	4.1	23
94	Health-Related Quality of Life in Patients with Adult-Onset Myotonic Dystrophy Type 1: A Systematic Review. Patient, 2019, 12, 365-373.	2.7	11
95	The Position of Neuromuscular Patients in Shared Decision Making. Report from the 235th ENMC Workshop: Milan, Italy, January 19-20, 2018. Journal of Neuromuscular Diseases, 2019, 6, 161-172.	2.6	7
96	Genetic determinants of disease severity in the myotonic dystrophy type 1 OPTIMISTIC cohort. Neurology, 2019, 93, e995-e1009.	1.1	71
97	Self-management program improves participation in patients with neuromuscular disease. Neurology, 2019, 93, e1720-e1731.	1.1	23
98	Insulin Signaling as a Key Moderator in Myotonic Dystrophy Type 1. Frontiers in Neurology, 2019, 10, 1229.	2.4	17
99	Strength training and aerobic exercise training for muscle disease. The Cochrane Library, 2019, 2019, CD003907.	2.8	44
100	Early onset as a marker for disease severity in facioscapulohumeral muscular dystrophy. Neurology, 2019, 92, e378-e385.	1.1	30
101	Structural white matter networks in myotonic dystrophy type 1. NeuroImage: Clinical, 2019, 21, 101615.	2.7	23
102	Single-cell RNA sequencing in facioscapulohumeral muscular dystrophy disease etiology and development. Human Molecular Genetics, 2019, 28, 1064-1075.	2.9	46
103	Functional impairments, fatigue and quality of life in RYR1-related myopathies: A questionnaire study. Neuromuscular Disorders, 2019, 29, 30-38.	0.6	20
104	Diagnostics of short tandem repeat expansion variants using massively parallel sequencing and componential tools. European Journal of Human Genetics, 2019, 27, 400-407.	2.8	12
105	Muscle MRI in a large cohort of patients with oculopharyngeal muscular dystrophy. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 576-585.	1.9	38
106	Reference values of maximum performance tests of speech production. International Journal of Speech-Language Pathology, 2019, 21, 56-64.	1.2	29
107	Ultrasound: A Potential Tool for Detecting of Fasciitis in Dermatomyositis and Polymyositis. Journal of Rheumatology, 2018, 45, 441.1-442.	2.0	5
108	Lifetime endogenous estrogen exposure and disease severity in female patients with facioscapulohumeral muscular dystrophy. Neuromuscular Disorders, 2018, 28, 508-511.	0.6	21

#	Article	IF	Citations
109	Hearing impairment in patients with myotonic dystrophy type 2. Neurology, 2018, 90, e615-e622.	1.1	11
110	Falls and resulting fractures in Myotonic Dystrophy: Results from a multinational retrospective survey. Neuromuscular Disorders, 2018, 28, 229-235.	0.6	19
111	Electrical impedance myography in facioscapulohumeral muscular dystrophy: A 1â€year followâ€up study. Muscle and Nerve, 2018, 58, 213-218.	2.2	15
112	Qualitative and Quantitative Aspects of Pain in Patients With Myotonic Dystrophy Type 2. Journal of Pain, 2018, 19, 920-930.	1.4	19
113	Prevalence and mutation spectrum of skeletal muscle channelopathies in the Netherlands. Neuromuscular Disorders, 2018, 28, 402-407.	0.6	40
114	MRI in sarcoglycanopathies: a large international cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 72-77.	1.9	55
115	Deep characterization of a common D4Z4 variant identifies biallelic DUX4 expression as a modifier for disease penetrance in FSHD2. European Journal of Human Genetics, 2018, 26, 94-106.	2.8	22
116	Specific muscle strength is reduced in facioscapulohumeral dystrophy: An MRI based musculoskeletal analysis. Neuromuscular Disorders, 2018, 28, 238-245.	0.6	11
117	Evidence of ER stress and UPR activation in patients with Brody disease and Brody syndrome. Neuropathology and Applied Neurobiology, 2018, 44, 533-536.	3.2	1
118	CONGENITAL MYOPATHIES: NEMALINE AND TITINOPATHIES. Neuromuscular Disorders, 2018, 28, S100-S101.	0.6	0
119	Effect of Mexiletine on Muscle Stiffness in Patients With Nondystrophic Myotonia Evaluated Using Aggregated N-of-1 Trials. JAMA - Journal of the American Medical Association, 2018, 320, 2344.	7.4	81
120	Quantitative muscle MRI and ultrasound for facioscapulohumeral muscular dystrophy: complementary imaging biomarkers. Journal of Neurology, 2018, 265, 2646-2655.	3.6	54
121	Consensus-based care recommendations for adults with myotonic dystrophy type 1. Neurology: Clinical Practice, 2018, 8, 507-520.	1.6	115
122	Facioscapulohumeral Dystrophy in Childhood: A Nationwide Natural History Study. Annals of Neurology, 2018, 84, 627-637.	5.3	21
123	NEW GENES, FUNCTIONS AND BIOMARKERS. Neuromuscular Disorders, 2018, 28, S31.	0.6	0
124	Phenotypeâ€genotype relations in facioscapulohumeral muscular dystrophy type 1. Clinical Genetics, 2018, 94, 521-527.	2.0	25
125	Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease. Orphanet Journal of Rare Diseases, 2018, 13, 155.	2.7	19
126	Second IVIg course in Guillainâ€BarrÃ© syndrome patients with poor prognosis (SIDâ€GBS trial): Protocol for a doubleâ€blind randomized, placeboâ€controlled clinical trial. Journal of the Peripheral Nervous System, 2018, 23, 210-215.	3.1	36

#	Article	IF	Citations
127	A 22-year follow-up reveals a variable disease severity in early-onset facioscapulohumeral dystrophy. European Journal of Paediatric Neurology, 2018, 22, 782-785.	1.6	8
128	Cis D4Z4 repeat duplications associated with facioscapulohumeral muscular dystrophy type 2. Human Molecular Genetics, 2018, 27, 3488-3497.	2.9	27
129	Autoantibodies to Cytosolic 5â€²-Nucleotidase 1A in Primary SjÃ¶grenâ€™s Syndrome and Systemic Lupus Erythematosus. Frontiers in Immunology, 2018, 9, 1200.	4.8	32
130	A family-based study into penetrance in facioscapulohumeral muscular dystrophy type 1. Neurology, 2018, 91, e444-e454.	1.1	33
131	FSHD type 2 and Bosma arhinia microphthalmia syndrome. Neurology, 2018, 91, e562-e570.	1.1	24
132	MRI-Guided Biopsy as a Tool for Diagnosis and Research of Muscle Disorders. Journal of Neuromuscular Diseases, 2018, 5, 315-319.	2.6	24
133	Repeatability and reliability of muscle relaxation properties induced by motor cortical stimulation. Journal of Applied Physiology, 2018, 124, 1597-1604.	2.5	5
134	Fatigue, not self-rated motor symptom severity, affects quality of life in functional motor disorders. Journal of Neurology, 2018, 265, 1803-1809.	3.6	48
135	Cognitive behavioural therapy with optional graded exercise therapy in patients with severe fatigue with myotonic dystrophy type 1: a multicentre, single-blind, randomised trial. Lancet Neurology, The, 2018, 17, 671-680.	10.2	95
136	Is fatigue a disease-specific or generic symptom in chronic medical conditions?. Health Psychology, 2018, 37, 530-543.	1.6	79
137	AB0776â€…Muscle ultrasonography: a potential new diagnostic tool for inflammatory myopathies. , 2018, , .		0
138	PGM1 deficiency: Substrate use during exercise and effect of treatment with galactose. Neuromuscular Disorders, 2017, 27, 370-376.	0.6	31
139	Cytosolic 5â€²-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis. Annals of the Rheumatic Diseases, 2017, 76, 862-868.	0.9	71
140	225th ENMC international workshop:. Neuromuscular Disorders, 2017, 27, 782-790.	0.6	20
141	The assessment of fatigue: Psychometric qualities and norms for the Checklist individual strength. Journal of Psychosomatic Research, 2017, 98, 40-46.	2.6	222
142	Respiratory function in facioscapulohumeral muscular dystrophy 1. Neuromuscular Disorders, 2017, 27, 526-530.	0.6	14
143	Respiratory pattern in a FSHD pediatric population. Respiratory Medicine, 2017, 126, 130-131.	2.9	0
144	Oculopharyngeal muscular dystrophy with frontotemporal dementia. European Geriatric Medicine, 2017, 8, 81-83.	2.8	3

#	Article	IF	Citations
145	The yield of diagnostic work-up of patients presenting with myalgia, exercise intolerance, or fatigue. Neuromuscular Disorders, 2017, 27, 243-250.	0.6	10
146	Involvement of pelvic girdle and proximal leg muscles in early oculopharyngeal muscular dystrophy. Neuromuscular Disorders, 2017, 27, 1099-1105.	0.6	17
147	Muscle fiber dysfunction contributes to clinical muscle weakness in inclusion body myositis. Neuromuscular Disorders, 2017, 27, S154.	0.6	0
148	The Brody disease cohort study: clarification of the phenotype. Neuromuscular Disorders, 2017, 27, S164.	0.6	0
149	Adding quantitative muscle MRI to the FSHD clinical trial toolbox. Neuromuscular Disorders, 2017, 27, S122.	0.6	1
150	Specific strength is reduced in facioscapulohumeral dystrophy muscles. An MRI-based musculoskeletal analysis. Neuromuscular Disorders, 2017, 27, S200.	0.6	0
151	Adding quantitative muscle MRI to the FSHD clinical trial toolbox. Neurology, 2017, 89, 2057-2065.	1.1	72
152	Muscle ultrasonography is a potential tool for detecting fasciitis in dermatomyositis and polymyositis: comment on the article by Yoshida etÂal. Arthritis and Rheumatology, 2017, 69, 2248-2249.	5.6	4
153	Clinical phenotype and outcome of hepatitis E virus associated neuralgic amyotrophy; an international retrospective comparative cohort study. Journal of Hepatology, 2017, 66, S59.	3.7	2
154	Hepatitis E virus infection and acute non-traumatic neurological injury: A prospective multicentre study. Journal of Hepatology, 2017, 67, 925-932.	3.7	80
155	Clinical phenotype and outcome of hepatitis E virusâ€“associated neuralgic amyotrophy. Neurology, 2017, 89, 909-917.	1.1	75
156	Brain imaging in myotonic dystrophy type 1. Neurology, 2017, 89, 960-969.	1.1	76
157	The cognitive profile of myotonic dystrophy type 1:ÂA systematic review and meta-analysis. Cortex, 2017, 95, 143-155.	2.4	82
158	Immunemediated necrotizing autoimmune myopathy: Dutch and Belgian experience. Neuromuscular Disorders, 2017, 27, S151.	0.6	0
159	Muscular fat fraction correlates with functionality in myotonic dystrophy type 1. Neuromuscular Disorders, 2017, 27, S180.	0.6	0
160	Retinal abnormalities in FSHD. Neuromuscular Disorders, 2017, 27, S201.	0.6	0
161	Slow relaxation kinetics of sarcomeres contribute to muscle slowness in NEM6 patients. Neuromuscular Disorders, 2017, 27, S230.	0.6	0
162	Early onset facioscapulohumeral dystrophy â€“ a systematic review using individual patient data. Neuromuscular Disorders, 2017, 27, 1077-1083.	0.6	39

#	Article	IF	Citations
163	Effects of Mindfulness-Based Stress Reduction on the Mental Health of Clinical Clerkship Students: A Cluster-Randomized Controlled Trial. Academic Medicine, 2017, 92, 1012-1021.	1.6	56
164	Recognizing the tenascinâ€X deficient type of Ehlersâ€“Danlos syndrome: a crossâ€sectional study in 17 patients. Clinical Genetics, 2017, 91, 411-425.	2.0	46
165	The Radboud Dysarthria Assessment: Development and Clinimetric Evaluation. Folia Phoniatrica Et Logopaedica, 2017, 69, 143-153.	1.1	35
166	Characteristics and natural history of oculopharyngeal muscular dystrophy (OPMD): The study protocol of â€˜OPMD Forteâ€™. Neuromuscular Disorders, 2016, 26, S139-S140.	0.6	3
167	The wrong end of the telescope: neuromuscular mimics of movement disorders (and vice versa). Practical Neurology, 2016, 16, 264-269.	1.1	11
168	The energetic study: Effectiveness of a self-management group programme to improve social participation in patients with neuromuscular disease and chronic fatigue. Neuromuscular Disorders, 2016, 26, S147.	0.6	0
169	Contractile dysfunction in permeabilized muscle fibers of NEM6 patients with the Dutch founder mutation in KBTBD13. Neuromuscular Disorders, 2016, 26, S134.	0.6	0
170	Monitoring creatine and phosphocreatine by 13C MR spectroscopic imaging during and after 13C4 creatine loading: a feasibility study. Amino Acids, 2016, 48, 1857-1866.	2.7	4
171	Integrating clinical and genetic observations in facioscapulohumeral muscular dystrophy. Current Opinion in Neurology, 2016, 29, 606-613.	3.6	10
172	The epidemiology of neuromuscular disorders: Age at onset and gender in the Netherlands. Neuromuscular Disorders, 2016, 26, 447-452.	0.6	17
173	Mutations in DNMT3B Modify Epigenetic Repression of the D4Z4 Repeat and the Penetrance of Facioscapulohumeral Dystrophy. American Journal of Human Genetics, 2016, 98, 1020-1029.	6.2	188
174	Quantitative MRI reveals decelerated fatty infiltration in muscles of active FSHD patients. Neurology, 2016, 86, 1700-1707.	1.1	61
175	No relevant excess prevalence of myotonic dystrophy type 2 in patients with suspected fibromyalgia syndrome. Neuromuscular Disorders, 2016, 26, 370-373.	0.6	5
176	Characterization of sarcoplasmic reticulum Ca2+ ATPase pumps in muscle of patients with myotonic dystrophy and with hypothyroid myopathy. Neuromuscular Disorders, 2016, 26, 378-385.	0.6	6
177	Patients with Systemic Sclerosis/polymyositis Overlap Have a Worse Survival Rate Than Patients Without It. Journal of Rheumatology, 2016, 43, 1838-1843.	2.0	21
178	Cytokine genes as potential biomarkers for muscle weakness in OPMD. Human Molecular Genetics, 2016, 25, 4282-4287.	2.9	3
179	Facioscapulohumeral dystrophy in children: design of a prospective, observational study on natural history, predictors and clinical impact (iFocus FSHD). BMC Neurology, 2016, 16, 138.	1.8	15
180	IMPLICATIONS OF ANTI-CN1A SEROTYPE IN INCLUSION BODY MYOSITIS. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.160-e1.	1.9	1

#	Article	IF	Citations
181	Getting the picture of facioscapulohumeral muscular dystrophy: Muscle magnetic resonance imaging and ultrasound. Neuromuscular Disorders, 2016, 26, S101.	0.6	0
182	Implementation and process evaluation of the energetic study. Neuromuscular Disorders, 2016, 26, S147-S148.	0.6	0
183	Gene variants in SMCHD1 and DNMT3B modify the risk for FSHD. Neuromuscular Disorders, 2016, 26, S152.	0.6	0
184	Changes in sarcomeric contractile function influence force generation in facioscapulohumeral muscular dystrophy. Neuromuscular Disorders, 2016, 26, S167.	0.6	0
185	Bilateral Vestibulopathy Aggravates Balance and Gait Disturbances in Sensory Ataxic Neuropathy, Dysarthria, and Ophthalmoparesis: A Case Report. Journal of Clinical Neuromuscular Disease, 2016, 18, 34-36.	0.7	3
186	Clinical practice considerations in facioscapulohumeral muscular dystrophy Sydney, Australia, 21 September 2015. Neuromuscular Disorders, 2016, 26, 462-471.	0.6	7
187	The Dutch patients' perspective on oculopharyngeal muscular dystrophy: A questionnaire study on fatigue, pain and impairments. Neuromuscular Disorders, 2016, 26, 221-226.	0.6	15
188	Mutationâ€specific effects on thin filament length in thin filament myopathy. Annals of Neurology, 2016, 79, 959-969.	5.3	54
189	Disease specificity of autoantibodies to cytosolic 5â€²-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Annals of the Rheumatic Diseases, 2016, 75, 696-701.	0.9	116
190	What's in a name? The clinical features of facioscapulohumeral muscular dystrophy. Practical Neurology, 2016, 16, 201-207.	1.1	81
191	Genetic defects in the hexosamine and sialic acid biosynthesis pathway. Biochimica Et Biophysica Acta - General Subjects, 2016, 1860, 1640-1654.	2.4	30
192	Double SMCHD1 variants in FSHD2: the synergistic effect of two SMCHD1 variants on D4Z4 hypomethylation and disease penetrance in FSHD2. European Journal of Human Genetics, 2016, 24, 78-85.	2.8	23
193	Overweight Is an Independent Risk Factor for Reduced Lung Volumes in Myotonic Dystrophy Type 1. PLoS ONE, 2016, 11, e0152344.	2.5	22
194	Muscle MRI correlates with histology and clinical features in patients with FSHD, OPMD and sIBM. Neuromuscular Disorders, 2015, 25, S295-S296.	0.6	0
195	Computerized quantification of facial weakness in facioscapulohumeral muscular dystrophy. Neuromuscular Disorders, 2015, 25, S214.	0.6	0
196	The Epidemiology of Neuromuscular Disorders: A Comprehensive Overview of the Literature. Journal of Neuromuscular Diseases, 2015, 2, 73-85.	2.6	200
197	Overlap laminopathy with mild neurogenic atrophy and overt muscular dystrophy. Neuromuscular Disorders, 2015, 25, S279.	0.6	0
198	Cognitive behaviour therapy plus aerobic exercise training to increase activity in patients with myotonic dystrophy type 1 (DM1) compared to usual care (OPTIMISTIC): study protocol for randomised controlled trial. Trials, 2015, 16, 224.	1.6	49

#	Article	IF	Citations
199	A2.4â€…Subcellular localisation of cytosolic 5â€™-nucleotidase 1A in cell lines and skeletal muscle: implications for inclusion body myositis. Annals of the Rheumatic Diseases, 2015, 74, A17.1-A17.	0.9	0
200	<scp>RYR</scp>1â€related myopathies: a wide spectrum of phenotypes throughout life. European Journal of Neurology, 2015, 22, 1094-1112.	3.3	111
201	Increased fascial thickness of the deltoid muscle in dermatomyositis and polymyositis: An ultrasound study. Muscle and Nerve, 2015, 52, 534-539.	2.2	30
202	Cell Membrane Integrity in Myotonic Dystrophy Type 1: Implications for Therapy. PLoS ONE, 2015, 10, e0121556.	2.5	21
203	Primary Cataract as a Key to Recognition of Myotonic Dystrophy Type 1. European Journal of Ophthalmology, 2015, 25, e46-e49.	1.3	9
204	Disease modifying factors in facioscapulohumeral muscular dystrophy: Protocol of the FSHD-FOCUS study. Neuromuscular Disorders, 2015, 25, S214-S215.	0.6	0
205	Effectiveness and cost-effectiveness of a self-management group program to improve social participation in patients with neuromuscular disease and chronic fatigue: protocol of the Energetic study. BMC Neurology, 2015, 15, 58.	1.8	15
206	Dynamic stability during level walking and obstacle crossing in persons with facioscapulohumeral muscular dystrophy. Gait and Posture, 2015, 42, 295-300.	1.4	6
207	Myotonic discharges discriminate chloride from sodium muscle channelopathies. Neuromuscular Disorders, 2015, 25, 73-80.	0.6	9
208	Effect of Suboptimal Sampling and Handling Conditions on Urinary Metabolic Profiles. Chromatographia, 2015, 78, 429-434.	1.3	2
209	Gait propulsion in patients with facioscapulohumeral muscular dystrophy and ankle plantarflexor weakness. Gait and Posture, 2015, 41, 476-481.	1.4	8
210	Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken. Acta Neuropathologica, 2015, 129, 611-624.	7.7	112
211	Combined N-of-1 trials to investigate mexiletine in non-dystrophic myotonia using a Bayesian approach; study rationale and protocol. BMC Neurology, 2015, 15, 43.	1.8	17
212	The individualized neuromuscular quality of life questionnaire: Cultural translation and psychometric validation for the Dutch population. Muscle and Nerve, 2015, 51, 496-500.	2.2	12
213	Statin-Induced Myopathy Is Associated with Mitochondrial Complex III Inhibition. Cell Metabolism, 2015, 22, 399-407.	16.2	180
214	Clinical Functional Capacity Testing in Patients With Facioscapulohumeral Muscular Dystrophy: Construct Validity and Interrater Reliability of Antigravity Tests. Archives of Physical Medicine and Rehabilitation, 2015, 96, 2201-2206.	0.9	4
215	PGM1 deficiency â€“ A heterogeneous myopathy with opportunities for treatment. Neuromuscular Disorders, 2015, 25, S188-S189.	0.6	0
216	Why are FSHD muscles weak? A novel role for sarcomeric proteins. Neuromuscular Disorders, 2015, 25, S213.	0.6	0

#	Article	IF	Citations
217	Axial myopathy in a patient with a heterozygous MSTN mutation. Neuromuscular Disorders, 2015, 25, S216.	0.6	0
218	Cost-effectiveness of shared medical appointments for neuromuscular patients. Neurology, 2015, 85, 619-625.	1.1	7
219	Inter-individual differences in CpG methylation at D4Z4 correlate with clinical variability in FSHD1 and FSHD2. Human Molecular Genetics, 2015, 24, 659-669.	2.9	130
220	The Epidemiology of Neuromuscular Disorders: A Comprehensive Overview of the Literature. Journal of Neuromuscular Diseases, 2015, 2, 73-85.	2.6	89
221	Distinct Disease Phases in Muscles of Facioscapulohumeral Dystrophy Patients Identified by MR Detected Fat Infiltration. PLoS ONE, 2014, 9, e85416.	2.5	125
222	Neuralgic amyotrophy and hepatitis E virus infection. Neurology, 2014, 82, 498-503.	1.1	150
223	Dysarthria and dysphagia are highly prevalent among various types of neuromuscular diseases. Disability and Rehabilitation, 2014, 36, 1285-1289.	1.8	42
224	Sporadic late-onset nemaline myopathy with MGUS. Neurology, 2014, 83, 2133-2139.	1.1	40
225	Shared medical appointments improve QOL in neuromuscular patients. Neurology, 2014, 83, 240-246.	1.1	25
226	Quantitative muscle ultrasound versus quantitative magnetic resonance imaging in facioscapulohumeral dystrophy. Muscle and Nerve, 2014, 50, 968-975.	2.2	47
227	LAMA2 mutations in adult-onset muscular dystrophy with leukoencephalopathy. Muscle and Nerve, 2014, 49, 616-617.	2.2	4
228	Feverâ€induced recurrent rhabdomyolysis due to a novel mutation in the ryanodine receptor type 1 gene. Internal Medicine Journal, 2014, 44, 819-820.	0.8	24
229	Skeletal muscle imaging in facioscapulohumeral muscular dystrophy, pattern and asymmetry of individual muscle involvement. Neuromuscular Disorders, 2014, 24, 1087-1096.	0.6	33
230	How Persons with a Neuromuscular Disease Perceive Employment Participation: A Qualitative Study. Journal of Occupational Rehabilitation, 2014, 24, 52-67.	2.2	15
231	Compound heterozygous mutations of the TNXB gene cause primary myopathy. Neuromuscular Disorders, 2014, 24, 88-89.	0.6	3
232	Both aerobic exercise and cognitive-behavioral therapy reduce chronic fatigue in FSHD. Neurology, 2014, 83, 1914-1922.	1.1	106
233	Trunk muscle involvement is most critical for the loss of balance control in patients with facioscapulohumeral muscular dystrophy. Clinical Biomechanics, 2014, 29, 855-860.	1.2	23
234	G.O.28. Neuromuscular Disorders, 2014, 24, 923-924.	0.6	0

#	Article	IF	Citations
235	Population-based incidence and prevalence of facioscapulohumeral dystrophy. Neurology, 2014, 83, 1056-1059.	1.1	278
236	G.P.131. Neuromuscular Disorders, 2014, 24, 840.	0.6	0
237	Scleroderma-polymyositis overlap syndrome versus idiopathic polymyositis and systemic sclerosis: a descriptive study on clinical features and myopathology. Arthritis Research and Therapy, 2014, 16, R111.	3.5	45
238	G.P.15. Neuromuscular Disorders, 2014, 24, 798-799.	0.6	2
239	Histological abnormalities induced by the electromyography needle. Neuromuscular Disorders, 2014, 24, 77-78.	0.6	0
240	Both aerobic exercise training and cognitive behavior therapy reduce chronic fatigue in patients with facioscapulohumeral muscular dystrophy: A randomized controlled trial. Annals of Physical and Rehabilitation Medicine, 2014, 57, e96.	2.3	4
241	High prevalence of incomplete right bundle branch block in facioscapulohumeral muscular dystrophy without cardiac symptoms. Functional Neurology, 2014, 29, 159-65.	1.3	18
242	Strength training and aerobic exercise training for muscle disease. The Cochrane Library, 2013, , CD003907.	2.8	130
243	Nuclear entrapment and extracellular depletion of PCOLCE is associated with muscle degeneration in oculopharyngeal muscular dystrophy. BMC Neurology, 2013, 13, 70.	1.8	15
244	A novel late-onset axial myopathy associated with mutations in the skeletal muscle ryanodine receptor (RYR1) gene. Journal of Neurology, 2013, 260, 1504-1510.	3.6	71
245	Determining the role of sarcomeric proteins in facioscapulohumeral muscular dystrophy: a study protocol. BMC Neurology, 2013, 13, 144.	1.8	12
246	SERCA1 protein expression in muscle of patients with Brody disease and Brody syndrome and in cultured human muscle fibers. Molecular Genetics and Metabolism, 2013, 110, 162-169.	1.1	29
247	Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis. Neuromuscular Disorders, 2013, 23, 540-548.	0.6	169
248	Autoantibodies to cytosolic 5â€²â€nucleotidase 1A in inclusion body myositis. Annals of Neurology, 2013, 73, 397-407.	5.3	206
249	Research priorities of patients with neuromuscular disease. Disability and Rehabilitation, 2013, 35, 405-412.	1.8	38
250	Neuromuscular properties of the thigh muscles in patients with ehlersâ€“danlos syndrome. Muscle and Nerve, 2013, 47, 96-104.	2.2	14
251	184th ENMC international workshop: Pain and fatigue in neuromuscular disorders. Neuromuscular Disorders, 2013, 23, 1028-1032.	0.6	13
252	The European NeuroMuscular Centre (ENMC): 20 years on â€¦. Neuromuscular Disorders, 2013, 23, 375-376.	0.6	4

#	Article	IF	Citations
253	Sarcomeric dysfunction contributes to muscle weakness in facioscapulohumeral muscular dystrophy. Neurology, 2013, 80, 733-737.	1.1	36
254	Intrinsic Epigenetic Regulation of the D4Z4 Macrosatellite Repeat in a Transgenic Mouse Model for FSHD. PLoS Genetics, 2013, 9, e1003415.	3.5	95
255	Symptomatic lipid storage in carriers for the PNPLA2 gene. European Journal of Human Genetics, 2013, 21, 807-815.	2.8	25
256	Child Neurology: Differential diagnosis of a low CSF glucose in children and young adults. Neurology, 2013, 81, e178-81.	1.1	18
257	Exertional hyperckemia might be the first manifestation of a genetic disorder. Muscle and Nerve, 2013, 48, 461-462.	2.2	0
258	A decline in PABPN1 induces progressive muscle weakness in Oculopharyngeal muscle dystrophy and in muscle aging. Aging, 2013, 5, 412-426.	3.1	49
259	Correlation analysis of clinical parameters with epigenetic modifications in the DUX4 promoter in FSHD. Epigenetics, 2012, 7, 579-584.	2.7	48
260	Titin-based stiffening of muscle fibers in Ehlers-Danlos Syndrome. Journal of Applied Physiology, 2012, 112, 1157-1165.	2.5	33
261	A frameshift mutation in LRSAM1 is responsible for a dominant hereditary polyneuropathy. Human Molecular Genetics, 2012, 21, 358-370.	2.9	55
262	Problems of Adults with a Mitochondrial Disease â€“ The Patientsâ€™ Perspective: Focus on Loss. JIMD Reports, 2012, 6, 85-94.	1.5	4
263	Best practice guidelines and recommendations on the molecular diagnosis of myotonic dystrophy types 1 and 2. European Journal of Human Genetics, 2012, 20, 1203-1208.	2.8	129
264	Generation of Isogenic D4Z4 Contracted and Noncontracted Immortal Muscle Cell Clones from a Mosaic Patient. American Journal of Pathology, 2012, 181, 1387-1401.	3.8	63
265	Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. Nature Genetics, 2012, 44, 1370-1374.	21.4	582
266	Skeletal muscle involvement in myotonic dystrophy type 2. A comparative muscle ultrasound study. Neuromuscular Disorders, 2012, 22, 492-499.	0.6	23
267	Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study. Orphanet Journal of Rare Diseases, 2012, 7, 73.	2.7	86
268	Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study. Orphanet Journal of Rare Diseases, 2012, 7, 88.	2.7	112
269	Exploring Employment in Consultation Reports of Patients With Neuromuscular Diseases. Archives of Physical Medicine and Rehabilitation, 2012, 93, 2276-2280.	0.9	4
270	Brody syndrome: A clinically heterogeneous entity distinct from Brody disease. Neuromuscular Disorders, 2012, 22, 944-954.	0.6	35

#	Article	IF	Citations
271	C.P.3 Genetic and clinical heterogeneity of RYR1-related myopathies in a cohort of 60 Dutch families with identification of 40 novel mutations. Neuromuscular Disorders, 2012, 22, 841.	0.6	0
272	G.P.108 Sarcomeric dysfunction contributes to muscle weakness in facioscapulohumeral muscular dystrophy. Neuromuscular Disorders, 2012, 22, 900-901.	0.6	0
273	Sleep disturbances in chronic progressive external ophthalmoplegia. European Journal of Neurology, 2012, 19, 176-178.	3.3	17
274	Severe Dejerineâ€Sottas disease with respiratory failure and dysmorphic features in association with a PMP22 point mutation and a 3q23 microdeletion. Journal of the Peripheral Nervous System, 2012, 17, 223-225.	3.1	1
275	Diagnostic yield of muscle fibre conduction velocity in myopathies. Journal of the Neurological Sciences, 2011, 309, 40-44.	0.6	6
276	Mitochondrial enzymes discriminate between mitochondrial disorders and chronic fatigue syndrome. Mitochondrion, 2011, 11, 735-738.	3.4	54
277	Disease impact in chronic progressive external ophthalmoplegia: More than meets the eye. Neuromuscular Disorders, 2011, 21, 272-278.	0.6	29
278	O.15 Mutations in the skeletal muscle ryanodine receptor (RYR1) gene presenting with exertional myalgia and rhabdomyolysis. Neuromuscular Disorders, 2011, 21, 748.	0.6	1
279	P2.44 Accelerated skeletal muscle ageing is a molecular signature in OPMD. Neuromuscular Disorders, 2011, 21, 673.	0.6	0
280	Coffee and muscle cramps. Neuromuscular Disorders, 2011, 21, 832.	0.6	0
281	The phenotype of the Gly94fsX222 PMP22 insertion. Journal of the Peripheral Nervous System, 2011, 16, 113-118.	3.1	5
282	Screening for antecedent Campylobacter jejuni infections and antiâ€ganglioside antibodies in idiopathic neuralgic amyotrophy. Journal of the Peripheral Nervous System, 2011, 16, 153-156.	3.1	12
283	Dutch myotonic dystrophy type 2 patients and a North-African DM2 family carry the common European founder haplotype. European Journal of Human Genetics, 2011, 19, 567-570.	2.8	7
284	High Frequency of Neuropathic Pain in Ehlers-Danlos Syndrome: An Association with Axonal Polyneuropathy and Compression Neuropathy?. Journal of Pain and Symptom Management, 2011, 41, e4-e6.	1.2	28
285	Fatigue is associated with muscle weakness in Ehlers-Danlos syndrome: an explorative study. Physiotherapy, 2011, 97, 170-174.	0.4	53
286	Deregulation of the ubiquitin-proteasome system is the predominant molecular pathology in OPMD animal models and patients. Skeletal Muscle, 2011, 1, 15.	4.2	40
287	Dominant Mutations in KBTBD13, a Member of the BTB/Kelch Family, Cause Nemaline Myopathy with Cores. American Journal of Human Genetics, 2011, 88, 122.	6.2	0
288	High disease impact of myotonic dystrophy type 2 on physical and mental functioning. Journal of Neurology, 2011, 258, 1820-1826.	3.6	26

#	Article	IF	Citations
289	Nature and frequency of respiratory involvement in chronic progressive external ophthalmoplegia. Journal of Neurology, 2011, 258, 2020-2025.	3.6	16
290	Effects of shared medical appointments on quality of life and cost-effectiveness for patients with a chronic neuromuscular disease. Study protocol of a randomized controlled trial. BMC Neurology, 2011, 11, 106.	1.8	10
291	Causes and consequences of cerebral small vessel disease. The RUN DMC study: a prospective cohort study. Study rationale and protocol. BMC Neurology, 2011, 11, 29.	1.8	154
292	Living with myotonic dystrophy; what can be learned from couples? a qualitative study. BMC Neurology, 2011, 11, 86.	1.8	91
293	Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology, 2011, 50, 2206-2213.	1.9	88
294	The astrologist's posture: a useful clinical observation. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 164-164.	1.9	3
295	Speech Pathology Interventions in Patients with Neuromuscular Diseases: A Systematic Review. Folia Phoniatrica Et Logopaedica, 2011, 63, 15-20.	1.1	12
296	Implementation of multidisciplinary advice to allied health care professionals regarding the management of their patients with neuromuscular diseases. Disability and Rehabilitation, 2011, 33, 787-795.	1.8	13
297	Mild Muscular Features in Tenascin-X Knockout Mice, A Model of Ehlersâ€“Danlos Syndrome. Connective Tissue Research, 2011, 52, 422-432.	2.3	26
298	73 Problems of Children and Adolescents with a Mitochondrial Disease, Their Parents and Siblings. The Patients Perspective.. Pediatric Research, 2010, 68, 40-40.	2.3	0
299	Dominant Mutations in KBTBD13, a Member of the BTB/Kelch Family, Cause Nemaline Myopathy with Cores. American Journal of Human Genetics, 2010, 87, 842-847.	6.2	143
300	TDP-43 plasma levels do not differentiate sporadic inclusion body myositis from other inflammatory myopathies. Acta Neuropathologica, 2010, 120, 825-826.	7.7	9
301	Isolated eyelid closure myotonia in two families with sodium channel myotonia. Neurogenetics, 2010, 11, 257-260.	1.4	22
302	Pain in Ehlers-Danlos Syndrome Is Common, Severe, and Associated with Functional Impairment. Journal of Pain and Symptom Management, 2010, 40, 370-378.	1.2	176
303	Fatigue Is a Frequent and Clinically Relevant Problem in Ehlers-Danlos Syndrome. Seminars in Arthritis and Rheumatism, 2010, 40, 267-274.	3.4	131
304	Effect of aerobic exercise training and cognitive behavioural therapy on reduction of chronic fatigue in patients with facioscapulohumeral dystrophy: protocol of the FACTS-2-FSHD trial. BMC Neurology, 2010, 10, 56.	1.8	45
305	Only fat infiltrated muscles in resting lower leg of FSHD patients show disturbed energy metabolism. NMR in Biomedicine, 2010, 23, 563-568.	2.8	43
306	Employment status of patients with neuromuscular diseases in relation to personal factors, fatigue and health status: A secondary analysis. Journal of Rehabilitation Medicine, 2010, 42, 60-65.	1.1	28

#	Article	IF	Citations
307	Molecular therapy in myotonic dystrophy: focus on RNA gain-of-function. Human Molecular Genetics, 2010, 19, R90-R97.	2.9	39
308	Poor sleep quality and fatigue but no excessive daytime sleepiness in myotonic dystrophy type 2. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 963-967.	1.9	43
309	Glucose transporter-1 deficiency syndrome: the expanding clinical and genetic spectrum of a treatable disorder. Brain, 2010, 133, 655-670.	7.6	356
310	The neglected brain in myotonic dystrophy types 1 and 2. Neurology, 2010, 74, 1090-1091.	1.1	3
311	Muscle characteristics and altered myofascial force transmission in tenascin-X-deficient mice, a mouse model of Ehlers-Danlos syndrome. Journal of Applied Physiology, 2010, 109, 986-995.	2.5	28
312	Postural instability in Charcot-Marie-Tooth type 1A patients is strongly associated with reduced somatosensation. Gait and Posture, 2010, 31, 483-488.	1.4	40
313	Radicular dysfunction due to spinal deformities in Marfan syndrome at older age: Three case reports. European Journal of Medical Genetics, 2010, 53, 35-39.	1.3	10
314	Increased plasticity of the nuclear envelope and hypermobility of telomeres due to the loss of Aâ€“type lamins. Biochimica Et Biophysica Acta - General Subjects, 2010, 1800, 448-458.	2.4	65
315	171st ENMC International Workshop: Standards of care and management of facioscapulohumeral muscular dystrophy. Neuromuscular Disorders, 2010, 20, 471-475.	0.6	88
316	O.12 A new member of the BTB/Kelch family of proteins is mutated in nemaline myopathy type 6 (NEM6). Neuromuscular Disorders, 2010, 20, 638.	0.6	0
317	Strength training and aerobic exercise training for muscle disease. , 2010, , CD003907.		30
318	Addendum: neuralgische amyotrofie Een deel van de tekst van dit addendum is een bewerking van een artikel dat is gepubliceerd in het â€˜Neurologen Vademecumâ€™, uitgegeven door Bohn Stafleu van Loghum, Houten. Meer specifieke informatie is te vinden in eerder gepubliceerde Orthopedische CasuÃ¯stiek, 2002; addendum: neuralgische amyotrofie (Nens van Alfen, Baziel van Engelen). , 2010, , 391-397.		0
319	Fast Responses to Stepping on an Unexpected Surface Height Depend on Intact Large-Diameter Nerve Fibers: A Study on Charcotâ€“Marieâ€“Tooth Type 1A Disease. Journal of Neurophysiology, 2009, 102, 1684-1698.	1.8	7
320	Treatment of the inflammatory myopathies: update and practical recommendations. Expert Opinion on Pharmacotherapy, 2009, 10, 1183-1190.	1.8	47
321	Neuromuscular involvement in various types of Ehlersâ€“Danlos syndrome. Annals of Neurology, 2009, 65, 687-697.	5.3	141
322	Common epigenetic changes of D4Z4 in contraction-dependent and contraction-independent FSHD. Human Mutation, 2009, 30, 1449-1459.	2.5	172
323	TDP-43 accumulation is common in myopathies with rimmed vacuoles. Acta Neuropathologica, 2009, 117, 209-211.	7.7	59
324	Increased plasma amyloid-Î²42 protein in sporadic inclusion body myositis. Acta Neuropathologica, 2009, 118, 429-431.	7.7	18

#	Article	IF	Citations
325	Joint hypermobility as a distinctive feature in the differential diagnosis of myopathies. Journal of Neurology, 2009, 256, 13-27.	3.6	47
326	Health status in non-dystrophic myotonias: close relation with pain and fatigue. Journal of Neurology, 2009, 256, 939-947.	3.6	31
327	Neuromuscular features in Marfan syndrome. Clinical Genetics, 2009, 76, 25-37.	2.0	22
328	Optimizing referral of patients with neuromuscular disorders to allied health care. European Journal of Neurology, 2009, 16, 562-568.	3.3	12
329	Skeletal Muscle Ultrasound: Correlation Between Fibrous Tissue and Echo Intensity. Ultrasound in Medicine and Biology, 2009, 35, 443-446.	1.5	456
330	Treatment for idiopathic and hereditary neuralgic amyotrophy (brachial neuritis). The Cochrane Library, 2009, , CD006976.	2.8	87
331	Vestibular and proprioceptive influences on trunk movements during quiet standing. Neuroscience, 2009, 161, 904-914.	2.3	43
332	Balance control in patients with distal versus proximal muscle weakness. Neuroscience, 2009, 164, 1876-1886.	2.3	61
333	Dysphagia is present but mild in myotonic dystrophy type 2. Neuromuscular Disorders, 2009, 19, 196-198.	0.6	29
334	Muscle ultrasound measurements and functional muscle parameters in non-dystrophic myotonias suggest structural muscle changes. Neuromuscular Disorders, 2009, 19, 462-467.	0.6	38
335	Long-Term Pain, Fatigue, and Impairment in Neuralgic Amyotrophy. Archives of Physical Medicine and Rehabilitation, 2009, 90, 435-439.	0.9	69
336	Classification of employment factors according to the International Classification of Functioning, Disability and Health in patients with neuromuscular diseases: A systematic review. Disability and Rehabilitation, 2009, 31, 2150-2163.	1.8	24
337	Sensorimotor Axonal Polyneuropathy Without Hepatic Failure in Erythropoietic Protoporphyria. Journal of Clinical Neuromuscular Disease, 2009, 11, 72-76.	0.7	3
338	Sensory Nerve Conduction Studies in Neuralgic Amyotrophy. American Journal of Physical Medicine and Rehabilitation, 2009, 88, 941-946.	1.4	48
339	Facioscapulohumeral muscular dystrophy. Current Opinion in Neurology, 2009, 22, 539-542.	3.6	40
340	Different types of fatigue in patients with facioscapulohumeral dystrophy, myotonic dystrophy and HMSN-I. Experienced fatigue and physiological fatigue. Neurological Sciences, 2008, 29, 238-240.	1.9	39
341	A natural history study of late onset spinal muscular atrophy types 3b and 4. Journal of Neurology, 2008, 255, 1400-1404.	3.6	158
342	Computer-aided visualization of muscle weakness distribution. Journal of Neurology, 2008, 255, 1670-1678.	3.6	4

#	Article	IF	Citations
343	Cervical myelopathy caused by retrograde intraneural dissection of anesthetic solution. Muscle and Nerve, 2008, 37, 546-547.	2.2	0
344	Muscle 3243Aâ†'G mutation load and capacity of the mitochondrial energyâ€generating system. Annals of Neurology, 2008, 63, 473-481.	5.3	25
345	In tandem analysis of CLCN1 and SCN4A greatly enhances mutation detection in families with non-dystrophic myotonia. European Journal of Human Genetics, 2008, 16, 921-929.	2.8	68
346	Identifying deficits in balance control following vestibular or proprioceptive loss using posturographic analysis of stance tasks. Clinical Neurophysiology, 2008, 119, 2338-2346.	1.5	60
347	Gastrointestinal involvement is frequent in Myotonic Dystrophy type 2. Neuromuscular Disorders, 2008, 18, 646-649.	0.6	50
348	Clinical and molecular overlap between myopathies and inherited connective tissue diseases. Neuromuscular Disorders, 2008, 18, 843-856.	0.6	76
349	D.P.4.02 Dysphagia in Myotonic Dystrophy type 2. Neuromuscular Disorders, 2008, 18, 796-797.	0.6	0
350	Clinical neurophysiology of fatigue. Clinical Neurophysiology, 2008, 119, 2-10.	1.5	207
351	Development of a tool to guide referral of patients with neuromuscular disorders to allied health services. Part one. Disability and Rehabilitation, 2008, 30, 855-862.	1.8	18
352	Development of a tool to guide referral of patients with neuromuscular disorders to allied health services. Part two. Disability and Rehabilitation, 2008, 30, 863-870.	1.8	14
353	A weak balance: the contribution of muscle weakness to postural instability and falls. Nature Clinical Practice Neurology, 2008, 4, 504-515.	2.5	179
354	Open-Label Trial of Anti-TNF-Î± in Dermato- and Polymyositis Treated Concomitantly with Methotrexate. European Neurology, 2008, 59, 159-163.	1.4	92
355	The Evidence for Occupational Therapy for Adults with Neuromuscular Diseases: A Systematic Review. OTJR Occupation, Participation and Health, 2008, 28, 12-18.	0.8	9
356	Transferrin and Apolipoprotein C-III Isofocusing Are Complementary in the Diagnosis of N- and O-Glycan Biosynthesis Defects. Clinical Chemistry, 2007, 53, 180-187.	3.2	50
357	Nucleoplasmic LAP2Î±â€“lamin A complexes are required to maintain a proliferative state in human fibroblasts. Journal of Cell Biology, 2007, 176, 163-172.	5.2	117
358	Ambulatory disabilities and the use of walking aids in patients with Hereditary Motor and Sensory Neuropathy type I (HMSN I). Disability and Rehabilitation: Assistive Technology, 2007, 2, 35-41.	2.2	5
359	Fasciculation Potentials in High-Density Surface EMG. Journal of Clinical Neurophysiology, 2007, 24, 301-307.	1.7	42
360	The Dutch neuromuscular database CRAMP (Computer Registry of All Myopathies and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62 Td (Poly	0.6	39

#	Article	IF	Citations
361	Reduced quantitative muscle function in tenascin-X deficient Ehlers-Danlos patients. Neuromuscular Disorders, 2007, 17, 597-602.	0.6	32
362	G.P.7.13 Gene expression profiling in a skeletal muscle cell model of oculopharyngeal muscular dystrophy reveals an extracellular matrix defect. Neuromuscular Disorders, 2007, 17, 809.	0.6	0
363	G.P.10.13 Genotype-phenotype correlations for the skeletal muscle chloride- and sodium-channelopathies. Neuromuscular Disorders, 2007, 17, 821-822.	0.6	0
364	C.P.2.02 Neuromuscular involvement in Ehlers-Danlos syndrome. Neuromuscular Disorders, 2007, 17, 843-844.	0.6	0
365	G.P.14.13 Gastrointestinal symptoms in myotonic dystrophy type 2. Neuromuscular Disorders, 2007, 17, 857-858.	0.6	0
366	M.P.4.08 Are oxidative capacity and glycolysis affected in X-linked phosphorylase b kinase deficiency?. Neuromuscular Disorders, 2007, 17, 861.	0.6	0
367	Caffeine and Muscle Cramps: A Stimulating Connection. American Journal of Medicine, 2007, 120, e1-e2.	1.5	5
368	Exercise Therapy and Other Types of Physical Therapy for Patients With Neuromuscular Diseases: A Systematic Review. Archives of Physical Medicine and Rehabilitation, 2007, 88, 1452-1464.	0.9	177
369	The development of a model of fatigue in neuromuscular disorders: A longitudinal study. Journal of Psychosomatic Research, 2007, 62, 571-579.	2.6	102
370	Experienced and physiological fatigue in neuromuscular disorders. Clinical Neurophysiology, 2007, 118, 292-300.	1.5	88
371	Referral of patients with neuromuscular disease to occupational therapy, physical therapy and speech therapy: Usual practice versus multidisciplinary advice. Disability and Rehabilitation, 2007, 29, 717-726.	1.8	40
372	Early diagnosis of ALS: The search for signs of denervation in clinically normal muscles. Journal of the Neurological Sciences, 2007, 263, 154-157.	0.6	21
373	Proteomics Approaches to Study Genetic and Metabolic Disorders. Journal of Proteome Research, 2007, 6, 506-512.	3.7	12
374	Contribution of central and peripheral factors to residual fatigue in Guillainâ€“BarrÃ© syndrome. Muscle and Nerve, 2007, 36, 93-99.	2.2	21
375	The mitochondrial 13513G>A mutation is most frequent in Leigh syndrome combined with reduced complex I activity, optic atrophy and/or Wolffâ€“Parkinsonâ€“White. European Journal of Human Genetics, 2007, 15, 155-161.	2.8	55
376	Contractile properties of knee-extensors in one single family with nemaline myopathy: central and peripheral aspects of muscle activation. Clinical Physiology and Functional Imaging, 2007, 27, 217-224.	1.2	4
377	Psychiatric disorders appear equally in patients with myotonic dystrophy, facioscapulohumeral dystrophy, and hereditary motor and sensory neuropathy type I. Acta Neurologica Scandinavica, 2007, 115, 265-270.	2.1	36
378	Warming up improves speech production in patients with adult onset myotonic dystrophy. Journal of Communication Disorders, 2007, 40, 185-195.	1.5	9

#	Article	IF	Citations
379	Warm-up phenomenon in myotonia associated with the V445M sodium channel mutation. Journal of Neurology, 2007, 254, 257-258.	3.6	13
380	Effects of training and albuterol on pain and fatigue in facioscapulohumeral muscular dystrophy. Journal of Neurology, 2007, 254, 931-940.	3.6	69
381	Chronic progressive external ophthalmoplegia caused by an m.4267A > G mutation in the mitochondrial tRNAIle. Journal of Neurology, 2007, 254, 1614-1615.	3.6	5
382	9a Addendum: neuralgische amyotrofie. , 2007, , 111-123.		0
383	Falls in patients with neuromuscular disorders. Journal of the Neurological Sciences, 2006, 251, 87-90.	0.6	48
384	Rhabdomyolysis Caused by an Inherited Metabolic Disease: Very Long-chain Acyl-CoA Dehydrogenase Deficiency. American Journal of Medicine, 2006, 119, 176-179.	1.5	40
385	Proteasome-mediated degradation of integral inner nuclear membrane protein emerin in fibroblasts lacking A-type lamins. Biochemical and Biophysical Research Communications, 2006, 351, 1011-1017.	2.1	31
386	Clinical applications of high-density surface EMG: A systematic review. Journal of Electromyography and Kinesiology, 2006, 16, 586-602.	1.7	236
387	BSCL2 mutations in two Dutch families with overlapping Silver syndrome-distal hereditary motor neuropathy. Neuromuscular Disorders, 2006, 16, 122-125.	0.6	29
388	Eosinophilic fasciitis in a child mimicking a myopathy. Neuromuscular Disorders, 2006, 16, 144-148.	0.6	30
389	Muscle slowness in a family with nemaline myopathy. Neuromuscular Disorders, 2006, 16, 477-480.	0.6	17
390	A case of neuromuscular mimicry. Neuromuscular Disorders, 2006, 16, 510-513.	0.6	14
391	No effect of folic acid and methionine supplementation on D4Z4 methylation in patients with facioscapulohumeral muscular dystrophy. Neuromuscular Disorders, 2006, 16, 766-769.	0.6	27
392	Drug treatment for myotonia. The Cochrane Library, 2006, , CD004762.	2.8	66
393	Permanent Loss of Cervical Spinal Cord Function Associated with the Posterior Approach. Anesthesia and Analgesia, 2006, 102, 330-331.	2.2	43
394	Relation between muscle fiber conduction velocity and fiber size in neuromuscular disorders. Journal of Applied Physiology, 2006, 100, 1837-1841.	2.5	93
395	Recurrent neuropathy associated with Ehlersâ€“Danlos syndrome. Journal of Neurology, 2006, 253, 670-671.	3.6	30
396	Comparison of CMT1A and CMT2: similarities and differences. Journal of Neurology, 2006, 253, 1572-1580.	3.6	23

#	Article	IF	Citations
397	Central adaptations during repetitive contractions assessed by the readiness potential. European Journal of Applied Physiology, 2006, 97, 521-526.	2.5	32
398	Involuntary painful muscle contractions in Satoyoshi syndrome: A surface electromyographic study. Movement Disorders, 2006, 21, 2015-2018.	3.9	19
399	Na+-K+-ATPase is not involved in the warming-up phenomenon in generalized myotonia. Muscle and Nerve, 2006, 33, 514-523.	2.2	18
400	Persistent increased risk for thymoma in myasthenia gravis associated with myositis. Muscle and Nerve, 2006, 34, 251-252.	2.2	5
401	Safety of the Posterior Approach to the Brachial Plexus. Anesthesia and Analgesia, 2006, 103, 1046.	2.2	0
402	The clinical spectrum of neuralgic amyotrophy in 246 cases. Brain, 2006, 129, 438-450.	7.6	572
403	Needle Electromyographic Findings in 98 Patients with Myositis. European Neurology, 2006, 55, 183-188.	1.4	40
404	Influence of Relatives on Fatigue Experienced by Patients with Facioscapulohumeral Dystrophy, Myotonic Dystrophy and HMSN-I. European Neurology, 2006, 56, 24-30.	1.4	11
405	Measurement of the Energy-Generating Capacity of Human Muscle Mitochondria: Diagnostic Procedure and Application to Human Pathology. Clinical Chemistry, 2006, 52, 860-871.	3.2	96
406	Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Annals of the Rheumatic Diseases, 2006, 65, 1635-1638.	0.9	289
407	Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2Â antigen. Annals of the Rheumatic Diseases, 2006, 65, 242-245.	0.9	124
408	Sensorineural Hearing Impairment in Patients with Pmp22 Duplication, Deletion, and Frameshift Mutations. Otology and Neurotology, 2005, 26, 405-414.	1.3	21
409	Statin-disclosed acid maltase deficiency. Journal of Internal Medicine, 2005, 258, 196-197.	6.0	29
410	High specificity of myositis specific autoantibodies for myositis compared with other neuromuscular disorders. Journal of Neurology, 2005, 252, 534-537.	3.6	36
411	Inclusion body myositis. Journal of Neurology, 2005, 252, 1448-1454.	3.6	118
412	Protein Complexes in the Archaeon Methanothermobacter thermautotrophicus Analyzed by Blue Native/SDS-PAGE and Mass Spectrometry. Molecular and Cellular Proteomics, 2005, 4, 1653-1663.	3.8	79
413	Serial Isoelectric Focusing as an Effective and Economic Way to Obtain Maximal Resolution and High-Throughput in 2D-Based Comparative Proteomics of Scarce Samples:Â Proof-of-Principle. Journal of Proteome Research, 2005, 4, 2364-2368.	3.7	3
414	The effect of dantrolene sodium in Very Long Chain Acyl-CoA Dehydrogenase Deficiency. Neuromuscular Disorders, 2005, 15, 844-846.	0.6	10

#	Article	IF	Citations
415	Disease Course of Charcot-Marie-Tooth Disease Type 2 and Comorbidityâ€"Reply. Archives of Neurology, 2004, 61, 1470.	4.5	0
416	Localization of 4q35.2 to the nuclear periphery: is FSHD a nuclear envelope disease?. Human Molecular Genetics, 2004, 13, 1857-1871.	2.9	90
417	Treatment of Dermatomyositis and Polymyositis with Anti-Tumor Necrosis Factor-Î±: Long-Term Follow-Up. European Neurology, 2004, 52, 61-63.	1.4	75
418	Molecular Analysis of Myophosphorylase Deficiency in Dutch Patients with McArdle's Disease. Annals of Human Genetics, 2004, 68, 17-22.	0.8	26
419	Fuel utilization in patients with very long-chain acyl-coa dehydrogenase deficiency. Annals of Neurology, 2004, 56, 279-283.	5.3	53
420	Muscleâ€fiber conduction velocity and electromyography as diagnostic tools in patients with suspected inflammatory myopathy: A prospective study. Muscle and Nerve, 2004, 29, 46-50.	2.2	33
421	Diminished central activation during maximal voluntary contraction in chronic fatigue syndrome. Clinical Neurophysiology, 2004, 115, 2518-2524.	1.5	51
422	Maintaining Constant Voluntary Force in Generalized Myotonia Despite Muscle Membrane Disturbances: Insights from a High-Density Surface EMG Study. Journal of Clinical Neurophysiology, 2004, 21, 114-123.	1.7	7
423	Polymyositis, invasion of non-necrotic muscle fibres, and the art of repetition. BMJ: British Medical Journal, 2004, 329, 1464-1467.	2.3	25
424	Myositis specific autoantibodies: changing insights in pathophysiology and clinical associations. Current Opinion in Rheumatology, 2004, 16, 692-9.	4.3	35
425	Variability in fibre properties in paralysed human quadriceps muscles and effects of training. Pflugers Archiv European Journal of Physiology, 2003, 445, 734-740.	2.8	58
426	Serum creatine kinase as predictor of clinical course in rhabdomyolysis: a 5-year intensive care survey. Intensive Care Medicine, 2003, 29, 1121-1125.	8.2	202
427	Oculopharyngeal muscular dystrophy with limb girdle weakness as major complaint. Journal of Neurology, 2003, 250, 1307-1312.	3.6	91
428	Llama-derived phage display antibodies in the dissection of the human disease oculopharyngeal muscular dystrophy. Journal of Immunological Methods, 2003, 279, 149-161.	1.4	30
429	Oculopharyngeal muscular dystrophy (OPMD) due to a small duplication in the PABPN1 gene. Human Mutation, 2003, 21, 553-553.	2.5	25
430	Nuclear envelope alterations in fibroblasts from LGMD1B patients carrying nonsense Y259X heterozygous or homozygous mutation in lamin A/C gene. Experimental Cell Research, 2003, 291, 352-362.	2.6	169
431	Protein S-100B, neuron-specific enolase (NSE), myelin basic protein (MBP) and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) and blood of neurological patients. Brain Research Bulletin, 2003, 61, 261-264.	3.0	122
432	Successful Treatment of Dermatomyositis and Polymyositis with Anti-Tumor-Necrosis-Factor-Alpha: Preliminary Observations. European Neurology, 2003, 50, 10-15.	1.4	143

#	Article	IF	Citations
433	The relation between daytime sleepiness, fatigue, and reduced motivation in patients with adult onset myotonic dystrophy. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 138-139.	1.9	25
434	A locus on chromosome 15q for a dominantly inherited nemaline myopathy with core-like lesions. Brain, 2003, 126, 1545-1551.	7.6	54
435	Nijmegen Breakage Syndrome: A Neuropathological Study. Neuropediatrics, 2003, 34, 189-193.	0.6	14
436	Proteomics and neuromuscular diseases: theoretical concept and first results. Annals of Clinical Biochemistry, 2003, 40, 9-15.	1.6	18
437	NIR spectroscopic measurement of local muscle metabolism during rhythmic, sustained, and intermittent handgrip exercise. , 2003, , .		4
438	Auditory Processing in Patients With Charcot-Marie-Tooth Disease Type 1A. Otology and Neurotology, 2003, 24, 872-877.	1.3	4
439	Quadriceps weakness in a family with nemaline myopathy: influence of knee angle. Clinical Science, 2003, 105, 585-589.	4.3	9
440	Disease Course of Charcot-Marie-Tooth Disease Type 2. Archives of Neurology, 2003, 60, 823.	4.5	42
441	Upregulation of Ca²⁺removal in human skeletal muscle: a possible role for Ca²⁺-dependent priming of mitochondrial ATP synthesis. American Journal of Physiology - Cell Physiology, 2003, 285, C1263-C1269.	4.6	8
442	The Effect of Coenzyme Q10 Therapy in Parkinson Disease Could Be Symptomatic. Archives of Neurology, 2003, 60, 1170.	4.5	30
443	Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 73, 766-768.	1.9	97
444	Muscle Uridine Diphosphate-Hexosamines Do Not Decrease Despite Correction of Hyperglycemia-Induced Insulin Resistance in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 5179-5184.	3.6	17
445	Halothane-induced Calcium Release in Cultured Human Skeletal Muscle Cells from a Family Susceptible to Malignant Hyperthermia with an Unidentified Mutation in Chromosome 19. Anesthesiology, 2002, 97, 272-274.	2.5	2
446	Diagnosis and Differential Diagnosis of Muscle Cramps: A Clinical Approach. Journal of Clinical Neuromuscular Disease, 2002, 4, 89-94.	0.7	15
447	Autoantibodies directed to novel components of the PM/Scl complex, the human exosome. Arthritis Research, 2002, 4, 134.	2.0	81
448	A new phenotype of autosomal dominant nemaline myopathy. Neuromuscular Disorders, 2002, 12, 13-18.	0.6	29
449	Skeletal muscle of mice with a mutation in slow Î±-tropomyosin is weaker at lower lengths. Neuromuscular Disorders, 2002, 12, 952-957.	0.6	23
450	Near-infrared spectroscopy in chronic progressive external ophthalmoplegia: Adipose tissue thickness confounds decreased muscle oxygen consumption. Annals of Neurology, 2002, 51, 272-273.	5.3	5

#	Article	IF	Citations
451	Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Annals of Neurology, 2002, 51, 369-372.	5.3	108
452	Concomitant dermatomyositis and myasthenia gravis presenting with respiratory insufficiency. Muscle and Nerve, 2002, 25, 293-296.	2.2	23
453	In vivo quantitative nearâ€infrared spectroscopy in skeletal muscle during incremental isometric handgrip exercise. Clinical Physiology and Functional Imaging, 2002, 22, 210-217.	1.2	117
454	Less is more: treatment of aggravating behaviour in myasthenia gravis patients with dysphagia. European Journal of Neurology, 2002, 9, 688-689.	3.3	2
455	Clinical and serological characteristics of 125 Dutch myositis patients. Journal of Neurology, 2002, 249, 69-75.	3.6	88
456	Calcium regulation and muscle disease. Journal of Muscle Research and Cell Motility, 2002, 23, 59-63.	2.0	51
457	HLA class I and II in Lambert-Eaton myasthenic syndrome without associated tumor. Human Immunology, 2001, 62, 809-813.	2.4	40
458	Decreased immunoglobulin class switching in nijmegen breakage syndrome due to the DNA repair defect. Human Immunology, 2001, 62, 1324-1327.	2.4	35
459	Propagation disturbance of motor unit action potentials during transient paresis in generalized myotonia: A high-density surface EMG study. Brain, 2001, 124, 352-360.	7.6	62
460	Performance of near-infrared spectroscopy in measuring local O₂ consumption and blood flow in skeletal muscle. Journal of Applied Physiology, 2001, 90, 511-519.	2.5	477
461	Myositis-specific autoantibodies: overview and recent developments. Current Opinion in Rheumatology, 2001, 13, 476-482.	4.3	50
462	Guillainâ€“BarrÃ© syndrome as presenting feature in a patient with lupus nephritis, with complete resolution after cyclophosphamide treatment. Nephrology Dialysis Transplantation, 2001, 16, 840-842.	0.7	18
463	The Regulation of Fine Movements in Patients with Charcot Marie Tooth, Type Ia: Some Ideas about Continuous Adaptation. Motor Control, 2001, 5, 200-214.	0.6	11
464	Autoantibody profiles in the sera of European patients with myositis. Annals of the Rheumatic Diseases, 2001, 60, 116-123.	0.9	330
465	Scheie Syndrome Presenting as Myopathy. Neuropediatrics, 2001, 32, 93-96.	0.6	4
466	Presence of Diarrhea and Absence of Tendon Xanthomas in Patients With Cerebrotendinous Xanthomatosis. Archives of Neurology, 2000, 57, 520.	4.5	86
467	Autoantibody Testing in the Evaluation of Idiopathic Inflammatory Myopathies. Journal of Clinical Neuromuscular Disease, 2000, 2, 1-2.	0.7	1
468	Familial inclusion body myositis with histologically confirmed sensorimotor axonal neuropathy. Journal of Neurology, 2000, 247, 882-884.	3.6	12

#	Article	IF	Citations
469	Possible mechanisms of muscle cramp from temporal and spatial surface EMG characteristics. Journal of Applied Physiology, 2000, 88, 1698-1706.	2.5	44
470	Epidemiology of inclusion body myositis in the Netherlands: A nationwide study. Neurology, 2000, 55, 1385-1388.	1.1	187
471	Idiopathic Neuralgic Amyotrophy in Children. A Distinct Phenotype Compared to the Adult Form. Neuropediatrics, 2000, 31, 328-332.	0.6	34
472	The relative prevalence of dermatomyositis and polymyositis in Europe exhibits a latitudinal gradient. Annals of the Rheumatic Diseases, 2000, 59, 141-142.	0.9	97
473	Cerebrotendinous Xanthomatosis: The Spectrum of Imaging Findings and the Correlation with Neuropathologic Findings. Radiology, 2000, 217, 869-876.	7.3	147
474	Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis. Brain, 2000, 123, 908-919.	7.6	219
475	Congenital fibre type disproportion a time-locked diagnosis: A clinical and morphological follow-up study. Clinical Neurology and Neurosurgery, 2000, 102, 97-101.	1.4	15
476	Study on the gene and phenotypic characterisation of autosomal recessive demyelinating motor and sensory neuropathy (Charcot-Marie-Tooth disease) with a gene locus on chromosome 5q23-q33. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 66, 569-574.	1.9	128
477	Tubular Aggregates. Archives of Neurology, 1999, 56, 1410.	4.5	6
478	Acquired neuromyotonia: superiority of plasma exchange over high-dose intravenous human immunoglobulin. Journal of Neurology, 1999, 246, 623-625.	3.6	64
479	Quantitative near-infrared spectroscopy discriminates between mitochondrial myopathies and normal muscle. Annals of Neurology, 1999, 46, 667-670.	5.3	42
480	Muscle function in a patient with Brody's disease. Muscle and Nerve, 1999, 22, 704-711.	2.2	11
481	Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis. Metabolism: Clinical and Experimental, 1999, 48, 233-238.	3.4	89
482	Quantitative nearâ€infrared spectroscopy discriminates between mitochondrial myopathies and normal muscle. Annals of Neurology, 1999, 46, 667-670.	5.3	14
483	Quantitative Measurement of Oxygen Consumption and Forearm Blood Flow in Patients with Mitochondrial Myopathies. Advances in Experimental Medicine and Biology, 1999, 471, 313-319.	1.6	9
484	Frequent occurrence of anti-tRNAHis autoantibodies that recognize a conformational epitope in sera of patients with myositis. Arthritis and Rheumatism, 1998, 41, 1428-1437.	6.7	26
485	A double missense mutation in the ATM gene of a Dutch family with ataxia telangiectasia. Human Genetics, 1998, 102, 187-191.	3.8	18
486	Intravenous immunoglobulin preparation increases myoplasmic calcium concentration by activating the dihydropyridineâ€“ryanodine receptor complex. Journal of the Neurological Sciences, 1998, 156, 35-40.	0.6	1

#	Article	IF	Citations
487	Postural changes, dysphagia, and systemic sclerosis. Annals of the Rheumatic Diseases, 1998, 57, 331-338.	0.9	8
488	<title>Validation of measurement protocols to assess oxygen consumption and blood flow in the human forearm by near-infrared spectroscopy</title>. , 1998, 3194, 133.		20
489	Acceleration in the Rate of CNS Remyelination in Lysolecithin-Induced Demyelination. Journal of Neuroscience, 1998, 18, 2498-2505.	3.6	127
490	Enhancement of central nervous system remyelination in immune and non-immune experimental models of demyelination. Multiple Sclerosis Journal, 1997, 3, 76-79.	3.0	12
491	Can human polyclonal immunoglobulin raise the threshold for convulsions in rats?. Seizure: the Journal of the British Epilepsy Association, 1996, 5, 171-174.	2.0	1
492	Are muscle cramps in Isaacs' syndrome triggered by human immunoglobulin?. Journal of Neurology, Neurosurgery and Psychiatry, 1995, 58, 393-393.	1.9	7
493	Ocular and Systemic Manifestations of Cerebrotendinous Xanthomatosis. American Journal of Ophthalmology, 1995, 120, 597-604.	3.3	67
494	White matter abnormalities in congenital muscular dystrophy. Journal of the Neurological Sciences, 1995, 129, 162-169.	0.6	16
495	Leukoencephalopathy with swelling in children and adolescents: MRI patterns and differential diagnosis. Neuroradiology, 1995, 37, 679-686.	2.2	71
496	Immunoglobulin treatment in epilepsy, a review of the literature. Epilepsy Research, 1994, 19, 181-190.	1.6	42
497	High-dose intravenous immunoglobulin treatment in cryptogenic West and Lennox-Gastaut syndrome; an add-on study. European Journal of Pediatrics, 1994, 153, 762-769.	2.7	59
498	Cerebrospinal fluid examinations in cryptogenic West and Lennox-Gastaut syndrome before and after intravenous immunoglobulin administration. Epilepsy Research, 1994, 18, 139-147.	1.6	9
499	Serologie HLA typing in cryptogenic Lennox-Gastaut syndrome. Epilepsy Research, 1994, 17, 43-47.	1.6	18
500	Polyclonal Ig: an immunopharmacon?. Trends in Immunology, 1994, 15, 341-342.	7.5	0
501	A second missense mutation in the mitochondrial ATPase 6 gene in Leigh's syndrome. Annals of Neurology, 1993, 34, 410-412.	5.3	239
502	Benzodiazepine Withdrawal Reaction in Two Children following Discontinuation of Sedation with Midazolam. Annals of Pharmacotherapy, 1993, 27, 579-581.	1.9	53
503	Light chain ratios and concentrations of serum immunoglobulins in children with epilepsy. Epilepsy Research, 1992, 13, 255-260.	1.6	13
504	Paediatric cerebrotendinous xanthomatosis. Journal of Inherited Metabolic Disease, 1992, 15, 374-376.	3.6	25

#	Article	IF	Citations
505	Familial adult-onset muscular dystrophy with leukoencephalopathy. Annals of Neurology, 1992, 32, 577-580.	5.3	10
506	Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis. Annals of Neurology, 1992, 32, 834-835.	5.3	98
507	Group medical appointments for people with physical illness. The Cochrane Library, 0, , .	2.8	0
508	An evaluation of 24â€…h Holter monitoring in patients with myotonic dystrophy type 1. Europace, 0, , .	1.7	1